Provider News
OncoLink Cancer Resource Home

 

 
OncoLink Cancer Resource Home

Provider News and Information  (update 8/19/08)

OncoLink Cancer Resource Home
Types of Cancer Home
OncoLink Cancer Resource
Cancer Treatment Information Physician List
OncoLink Cancer Resource
Coping with Cancer MCC Staff
OncoLink Cancer Resource
Cancer Clinical Trials Matching Service Provider News
OncoLink Cancer Resource
Cancer Resources and News Women's News
OncoLink Cancer Resource
Ask the Cancer Experts Men's News
OncoLink Cancer Resource
OncoLink Cancer Library Treatment Protocols
OncoLink Cancer Resource
Cancer and Oncology Sponsors Cancer Control Protocols
OncoLink Cancer Resource
Giving to Oncolink's Cancer Resources Radiation Oncology
About Oncolink's Cancer Resources Upcoming Protocols
OncoLink
Giving to Oncolink's Cancer Resources Closed Protocols
Giving to Oncolink's Cancer Resources Related Links
   
 


 

 

MCC Administration

Benjamin Marchello, M.D.                 Principal Investigator bmarchello@hocnr.com

Grant Harrer, MD                               Co-Principal Investigator drharrer@benefis.net

James Burke, MD                                   NCCTG Group Lead jburke@billingsclinic.org

James Hueftle, MD                                 SWOG Group Lead jhueftle@prodigy.net

Thomas Warr, MD                                  NSABP Group Lead thomas.warr@gfclinic.com

David Myers, MD                                   Cancer Control Group Lead dmyers01@gmail.com


News and Information


Cooperative Group Meetings

NCCTG          October 20 - 23, 2008                                  SWOG            Oct 29 - Nov 2, 2008                                  RTOG             January 15 -18, 2009                                              NSABP           June 13 - 15, 2008                                                           See Cooperative Group websites for registration                                     Travel on this page for MCC policy and reimbursement information

Common Toxicity Criteria Tables

 

New Protocols Opened  (Updated 8/25/08)

Note:  JMA.17R now available for other patients not previously on JMA.17

 

    Information on the closure of     protocols using cetuximab

 

S9921 Closed by DSM due to unexpected late side effects (Press Release)

Travel  

MCC Travel Policy                                     Travel Request Form                                  Travel Reimbursement Form

Investigational Agents                      PMB Agent Distribution Policy

 

New Protocols              

                              Cancer Control 

NCCTG N07C1     Protocol   A Phase III, Randomized, Double-Blind, Placebo-controlled Evaluation of Pregabalin for Alleviating Hot Flashes

RTOG R0614   Protocol    A Randomized, Phase III, Double-blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-brain Radiotherapy

                                              

           

                                   Prevention

                                                  None

 
                                   Treatment Protocols

NCCTG N0779     Protocol   Phase II Study of Vorinostat (SAHA) in combination with Bortezomib (PS-341) in Patients with Recurrent Glioblatoma Multiforme

 

RTOG R0436    Protocol   A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery

CTSU C30610    Protocol    Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

 

 

 

 

 

OncoLink Cancer Resource Home